{
  "docId": "019de517-ef27-7380-abf1-7804147a21c1",
  "docSlug": "35bb8af5e32b82874d7685e3939f2cc9",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 39 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 39,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "revenue_buildup",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-ef27-7380-abf1-7804147a21c1/9",
  "deckHref": "/decks/019de517-ef27-7380-abf1-7804147a21c1",
  "deckJsonHref": "/decks/019de517-ef27-7380-abf1-7804147a21c1.json",
  "deckAnchorHref": "/decks/019de517-ef27-7380-abf1-7804147a21c1#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.339,
        "w": 0.249,
        "x": 0.048,
        "y": 0.186
      },
      "kind": "chart",
      "text": "$996M 4Q22, $1,173M 4Q23",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2f9af65-79f2-4117-89eb-b2c6e0517f51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.169,
        "x": 0.759,
        "y": 0.186
      },
      "kind": "chart",
      "text": "Pharmaceuticals2 $307M (74% U.S., 26% International)",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e7cbb79-c17c-4991-8492-672c8bdf6b42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.169,
        "x": 0.549,
        "y": 0.186
      },
      "kind": "chart",
      "text": "Surgical $204M (51% Implantables, 24% Equipment, 25% Consumables/Other)",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b6805d5-7d5b-413f-82e9-914db15a290f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.169,
        "x": 0.339,
        "y": 0.186
      },
      "kind": "chart",
      "text": "Vision Care2 $662M (66% Consumer, 34% Contact Lens)",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bb559bd-03ed-4869-8d67-00d911cfbb0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.21,
        "x": 0.74,
        "y": 0.665
      },
      "kind": "list",
      "text": "+66% Strong early Miebo® performance, investing to drive growth\nRelaunched Xiidra®, $106M revenue contribution in 4Q23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49d29b1c-1db9-4902-9f80-e93aae0dd203",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.21,
        "x": 0.32,
        "y": 0.665
      },
      "kind": "list",
      "text": "+8% Growth momentum in Lumify®, Eye Vitamins, Dry Eye, Daily SiHy\nLens portfolio (+1%, +3% cc¹), excluding Lynchburg disruptions (+7%, +9% cc¹)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ad6e3e6-5246-44e7-acad-3a417c84a657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.21,
        "x": 0.53,
        "y": 0.665
      },
      "kind": "list",
      "text": "+7% Solid demand in Consumables and Equipment, supply remains focus area\nContinuing growth in Premium IOLs, offset by EyeCee One IOL recall",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfcbf0c6-7812-4416-a417-7340be77f821",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.079,
        "w": 0.201,
        "x": 0.065,
        "y": 0.59
      },
      "kind": "list",
      "text": "+18% 4Q23 Revenue Growth Reported, +19% 4Q23 Revenue Growth Constant Currency¹",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d65c4b73-4c03-4b63-9dac-64c69c6dd0a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.21,
        "x": 0.069,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "Strong revenue growth across all segments and key product franchises\nApprox. -$9M revenue FX headwinds",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cb670cb-baea-4c8b-a976-685765063dda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.165,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Constant currency. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the\nreported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of\nsimilar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03f241ff-fea8-4536-9696-16cf8d7a3a50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.429,
        "x": 0.045,
        "y": 0.06
      },
      "kind": "title",
      "text": "4Q23 Revenue Drivers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "243a1910-335f-46ec-9281-307df6a4e704",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "d6fbc6e1-824b-4798-aac9-27095aa32da2",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The financial results and segment performance create a desire to learn more",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 9,
      "name": "Zoom In",
      "slug": "06-zoom-in",
      "bestFor": "Technical deep-dives, case studies, detailed analysis",
      "matchId": "11fd2762-3225-4b01-8777-53698056e053",
      "evidence": "The document zooms in on revenue drivers and financial performance",
      "position": 0,
      "objective": "What drives revenue growth?",
      "structure": "The Big Picture -> Key Area of Focus -> Specific Detail -> Implication",
      "confidence": 0.7,
      "description": "Start broad, then progressively focus on specific details that prove your point"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}